VANCOUVER, British Columbia, Canada, May 10, 2004 (PRIMEZONE) -- Dr. John Todd, President of ProtoKinetix, Inc. (OTCBB:PKTX) is honored to announce today that Jean-Charles Quirion has agreed to serve on the Company's Scientific Advisory Board. Dr. Quirion brings to ProtoKinetix twenty years of research experience in synthetic organic chemistry and ten years of management of industrial projects. His extensive contributions in the synthesis of new chemical entities for New Drug Discovery in the areas of cancer will be of enormous benefit to ProtoKinetix development of therapeutics for the treatment of malignancies. Jean-Charles' research work has resulted in the development of several new substances for anti-HIV, anti-inflammatory and anti-cancer drugs. This announcement is the first of many developments brought about by Dr. Todd's recent meetings in Europe with ProtoKinetix' Directors and collaborators. A look at Jean-Charles Quirion's extensive resume on the company's web site at www.protokinetix.com will illustrate the quality of the brain trust that is being assembled.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President